8-K: Catheter Precision Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Update

Catheter Precision reports its financial results and operational progress for the year ending December 31, 2024, highlighting sales team restructuring, LockeT's market introduction, and progress in clinical studies.

Summary

• Catheter Precision announced its financial results and operational update for the period ending December 31, 2024.
• A new Chief Commercial Officer joined in Q2 2024, leading to a replacement of the majority of the prior sales team, with training completed in Q3 2024.
• The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year.
• 26 institutions were either conducting or had completed their evaluation of LockeT at year end.
• The company completed the audits for LockeT's CE Mark in Q4 2024, with the CE Mark anticipated in Q2 2025.
• EU LockeT sales are expected to begin in Q3 2025.
• VIVO marketing and sales progress continues in the US and multiple international markets.
• Two clinical studies were published in 2024, along with the first LockeT journal manuscript and two abstracts.
• Additional clinical studies of both VIVO and LockeT are ongoing or planned for 2025.
• Multiple IRB approvals were received in Q4 2024 and Q1 2025 for new LockeT studies.
• A Randomized Controlled Trial (RCT) is planned for VIVO to begin in Q3 2025.
• Total assets on December 31, 2024, were $27.7 million.
• Total shareholders equity on December 31, 2024, was $11.8 million.
• Total outstanding shares of common stock on December 31, 2024, were 8,004,633.
• Fourth quarter revenue was $149 thousand, a sequential increase of 55% over Q3 2024.
• Full year 2024 revenue was $420 thousand.
• Net loss for fourth quarter was $5.6 million, of which $3.1 million were non-cash charges.
• Total net loss for 2024 was $16.6 million, of which $7.5 million were non-cash charges.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the company's progress in sales team restructuring, product development, and clinical studies. However, the significant net loss and reliance on future financing temper the overall outlook.

Positives

• The company successfully restructured its sales team under a new Chief Commercial Officer.
• LockeT sales commenced and grew sequentially throughout 2024.
• The company is expanding its market reach with VIVO in the US and internationally.
• Clinical studies are ongoing or planned for both VIVO and LockeT to further demonstrate efficacy.
• Fourth quarter revenue showed a significant increase of 55% compared to the previous quarter.

Negatives

• The company experienced a net loss of $16.6 million for the full year 2024.
• The company had to replace the majority of the prior sales team.

Risks

• The company's expectations regarding clinical trial results and timelines may not materialize.
• The company may not have sufficient liquidity to fund operations without additional financing or strategic transactions.
• The company's revenues may depend on customers' receipt of adequate reimbursement from private insurers and government-sponsored healthcare programs.
• The company faces competition from companies with substantially greater resources.
• The company's future operating results depend on its ability to obtain components in sufficient quantities on commercially reasonable terms.

Future Outlook

The company anticipates positive sales revenue results in the coming quarters, expects publication of trial results, and anticipates growth of the ventricular market and its contribution to it.

Management Comments

• We are very pleased with the results of 2024, said David Jenkins, CEO of Catheter Precision.
• 2024 was a transitional year for us while we rebuilt and trained a new sales team and advanced our clinical programs.
• We established multiple new repeat customers and partners that share our belief that VIVO and LockeT are transformative products for the EP market.
• We remain quite excited about the growth and opportunities within our field of cardiac electrophysiology.

Industry Context

Catheter Precision operates in the competitive electrophysiology market, focusing on innovative solutions for cardiac arrhythmias. The company's progress with LockeT and VIVO reflects a broader industry trend towards minimally invasive procedures and advanced mapping technologies.

Comparison to Industry Standards

• Comparing Catheter Precision to larger players like Boston Scientific, Medtronic, or Abbott in the electrophysiology market reveals a significant difference in scale and resources.
• While these larger companies have established product portfolios and global distribution networks, Catheter Precision focuses on niche areas with its VIVO and LockeT devices.
• For example, Boston Scientific's Rhythmia mapping system is a direct competitor to VIVO, but VIVO's non-invasive approach offers a unique selling point.
• Similarly, LockeT competes with existing vascular closure devices, but its external compression design aims to improve safety and ease of use.
• The $420 thousand annual revenue is significantly lower than the multi-billion dollar revenues of the industry giants, highlighting the company's early stage and growth potential.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and product development progress.
• Employees may be affected by the sales team restructuring.
• Customers (hospitals and physicians) may benefit from the innovative VIVO and LockeT devices.
• Suppliers may see increased demand as the company expands its product sales.

Next Steps

• Obtain CE Mark for LockeT in Q2 2025.
• Begin EU LockeT sales in Q3 2025.
• Initiate Randomized Controlled Trial (RCT) for VIVO in Q3 2025.
• Continue ongoing and planned clinical studies for VIVO and LockeT.
• Publish trial results.

Key Dates

Keywords

Catheter Precision, VTAK, LockeT, VIVO, electrophysiology, medical device, financial results, revenue, clinical studies, CE Mark